Table 1.
CXCL13 impact across different types of cancer.
| Cancer type | Pro-tumor | Antitumor |
|---|---|---|
| Breast cancer |
In vitro addition to MDA-MB-231 cells increases MMP expression Model: Mouse cancer cells (68) |
Correlated with greater survival and immune tumor infiltration Model: ex vivo analysis of human breast cancer tissue (81) HER2+/TNBC: Correlated with better prognosis Model: Human clinical data (82, 83) |
| Genitourinary cancers | Clear cell renal carcinoma: Promotes PI3K/AKT signaling (CXCR5+) Model: human tissue analysis (14) Prostate cancer: Enhances ECM remodeling and bone metastasis (CXCR5+) Model: human engineered cell lines and xenograft mouse model (76) |
Ovarian cancer: Correlated with better prognosis Model: Human healthy and cancerous tissue cDNA expression data (84) |
| Colorectal cancer | N/A | Correlated with improved survival Model: Human clinical data (15) |
| OSCC | Increases MMP expression and bone invasion (CXCR5+) Model: Human-derived OSCCs cells and xenograft mouse model (75) |
N/A |
| Liver cancer | Liver Cancer: Drives Wnt signaling (CXCR5+) Model: in vitro analysis of human samples (77) |
N/A |
| Leukemia | B-CLL and B-ALL: Promotes apoptosis resistance Model: in vitro analysis of human samples (78, 79) |
N/A |